Fractyl Health reported six‑month REMAIN‑1 results showing that its endoscopic procedure Revita reduced weight regain after GLP‑1 discontinuation by ~70% versus sham in patients who stopped incretin therapy after substantial weight loss. The trial readout positions Revita as a potential interventional option for sustained weight control when pharmacologic therapy is withdrawn. The procedure targets metabolic adaptation after GLP‑1 cessation and may provide an alternative for patients who cannot continue or do not tolerate long‑term incretin therapy. The results stem from a randomized, sham‑controlled design, and Fractyl highlighted the magnitude of effect on weight recidivism. If further validated, Revita could enter a niche between medical and surgical obesity treatments, offering a minimally invasive, device‑based option for weight‑maintenance. Payers and clinicians will evaluate durability, safety, and cost‑effectiveness relative to ongoing pharmacotherapy and bariatric procedures. Upcoming larger trials and longer follow‑up will be decisive for reimbursement discussions and commercial adoption in a market shaped by GLP‑1 drugs’ rapid uptake.